MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival of post-menopausal women with hormone receptor-positive metastatic breast cancer, compared to the hormone therapy alone.
Go to Source